Ariad Pharmaceuticals, Inc. Announces Initial Results Of Phase 1b Clinical Trial Of Oral AP23573 In Patients With Relapsed And/Or Refractory Cancers

PHILADELPHIA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 17, 2005--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the oral dosage form of its novel mTOR inhibitor, AP23573, can be administered safely using several daily and intermittent dosing schedules and achieves blood levels and mTOR inhibition consistent with those observed with intravenous administration.